Lymphoma & blood cancers – Cancer Trials Ireland

Cancer Trials Ireland > Cancer Trials > Lymphoma & blood cancers

Isa-RVD

Name	No.	For Patients with	Purpose
Isa-RVD	19-34	The target population for this study are patients with newly diagnosed multiple myeloma for high dose therapy and autologous stem cell transplant. Patients will have a confirmed diagnosis of multiple myeloma, based on standard IMWG criteria.	This study is a Phase II, multi-centre, single-arm, open-label study to evaluate the efficacy and safety of the combination regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in patients with newly diagnosed multiple myeloma

CPD-DARA

Name	No.	For Patients with	Purpose
CPD-DARA	19-17	The target population for this study are patients with relapsed/refractory multiple myeloma (MM). Patients will have a confirmed diagnosis of MM, with measurable disease as per IMWG criteria, in the second relapse and beyond (third line of therapy and beyond)	This study is a Phase Ib, open label, single arm, adaptive multi-centre clinical study of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in patients with relapsed/refractory multiple myeloma

MOR208C310

Name	No.	For Patients with	Purpose
MOR208C310	20-35	Newly-diagnosed diffuse large B-cell lymphoma (DLBCL).	This Study is comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL).

INDEPENDENCE ACE-536-MF-002

Name	No.	For Patients with	Purpose
INDEPENDENCE ACE-536-MF-002	20-34	Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions	This Study is to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions.

HOVON 156

Name	No.	For Patients with	Purpose
HOVON 156	19-16	Newly diagnosed diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with FLT3 mutations eligible for intensive chemotherapy	This trial will compare Gilteritinib and midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy

HOVON 150

Name	No.	For Patients with	Purpose
HOVON 150	19-18	Newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy	This trial will compare ivosidenib and enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy

BCNI GMI-1271-301

Name	No.	For Patients with	Purpose
BCNI GMI-1271-301	21-08	Relapsed/Refractory Acute Myeloid Leukemia (AML)	This Study is to Determine the Effficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukaemia

CLL17

Name	No.	For Patients with	Purpose
CLL17	20-22	Previously untreated Chronic Lymphocytic Leukaemia (CLL)	This trial will compare the efficacy of continuous ibrutinib monotherapy with fixed-duration venetoclax plus obinutuzumab and fixed-duration ibrutinib plus venetoclax in patients with previously untreated CLL

MO40598

Name	No.	For Patients with	Purpose
MO40598	CTRIAL-IE 18-47	Lymphoma.	This study will evaluate the safety and efficacy of Polatuzumab Vedotin (Pola) in combination with Mabthera plus Gemcitabine plus Oxaliplatin (R-GemOx) versus R-GemOx

FEDR-MF-002/FREEDOM-2

Name	No.	For Patients with	Purpose
FEDR-MF-002/FREEDOM-2	CTRIAL-IE 19-40	Primary Myelofibrosis, Post-PV or Post-ET Myelofibrosis	This study will assess the efficacy and safety of fedratinib compared to best available therapy.